Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It? (NYSE:NVO)
Summary
Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership. See why NVO stock is a Sell.
Description
Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership. See why NVO stock is a Sell.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source